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Abstract
Background: The human papilloma viruses (HPVs) are DNA viruses associated with benign and malignant lesions
of skin and mucous membranes. The HPVs has been implicated as the cause of virtually all cervical cancers
worldwide but studies showed that these viruses can cause numerous cancers in several tissues including Oral
Squamous Cell Carcinoma (OSCC). At least 90 % of HPV-positive OSCCs are associated with high-risk (or oncogenic)
HPV-16 and oral infection confers an approximate 50-fold increase in risk for HPV-positive OSCC. HPV-positive
OSCCs are associated with sexual behaviors in contrast to HPV-negative OSCCs that are associated with chronic
tobacco and alcohol use. The aim of this study was to estimate the prevalence of HPV-DNA in saliva samples
collected from women in which it has been previously established the HPV infection of the cervix with relative
genotyping and, then, to study the possible correlation.
Methods: Saliva samples were collected from 100 women with HPV cervical lesions, aged between 22 and 52 years
old, and 25 healthy women with normal cytology (control group), aged between 20 and 49 years old. PCR assay
was used to detect HPV DNA.
Results: The prevalence of oral HPV infection in saliva samples was 24 % in women with HPV cervical lesions
while in the control group was 8 %. It has been demonstrated a strong association between high grade squamous
intraepithelial lesion and oral infection due to HPV16 and 18, that are the most frequently detected HPV genotypes.
Conclusion: This study shows that patients with genital HPV infection are at risk for oral infection and,
consequently, for the development of OSCC.
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Background
The human papilloma viruses (HPVs) are DNA viruses
that infect squamous epithelial cells. They constitute a
group of more than 100 different genotypes associated
with benign and malignant lesions of skin and mucous
membranes. These viruses are divided in two groups on
the basis of their epidemiological association with the
development of cervical carcinoma: high-risk HPVs, that
include the genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66 and 68 and low-risk HPVs such as the ge-
notypes 6, 11, 42, 43 and 44. The HPV-DNA contains
sequences that encodes two proteins with oncogenic
capacity, E6 and E7, that exhibit their effect by disrupt-
ing the function of two tumor suppressor genes, p53
and pRb respectively, causing defective cell apoptosis
and uncontrolled cell growth [1]. The HPVs has been
implicated as the cause of virtually all cervical cancers
worldwide [2] although they can infect several cell types
causing various intraepithelial neoplasias [3–6]. Oral
cancer holds the eighth position in the cancer incidence
ranking worldwide [7]. Of all head and neck cancers,
Oral Squamous Cell Carcinoma (OSCC) is the most
common malignant epithelial neoplasia of oral cavity
(90 %); this represent approximately 5 % in men and 2 %
in women considering all malignancies [8]. At least 90 %
of HPV-positive OSCCs are associated with high-risk (or
oncogenic) HPV-16 [9] and oral infection confers an
approximate 50-fold increase in risk for HPV-positive
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OSCC [3]. The incidence of OSCC has significantly in-
creased over the last 3 decades in several countries, in
particular, the incidence of HPV-positive OSCC in-
creased by 225 % (from 0.8 per 100 000 to 2.6 per 100
000), predominantly among young individuals, and white
men [10]. HPV-positive OSCCs are associated with sex-
ual behavior in contrast to HPV-negative OSCCs that
are associated with chronic tobacco and alcohol use [3].
Recently, besides the traditional risk factors for develop-
ing oropharyngeal cancer (tobacco use and heavy alcohol
consumption), HPVs are identified as an independent
risk factor in the onset of pre-cancerous and cancerous
oropharyngeal lesions. It is likely, in fact, that HPV may
modulate the malignancy process in some tobacco- and
alcohol-induced oropharyngeal cancers, but may also be
the primary oncogenic factor for inducing carcinogenesis
in a subset of patients without these traditional risk fac-
tors [3, 4]. Of all the HPV genotypes, 24 are involved in
the development of benign and malignant lesions of the
oral cavity [11, 12]. In particular, HPV16, and to a lesser
extent HPV18, are most commonly identified from oral
biopsies [13, 14]. International studies have evaluated
HPV prevalence in healthy adults using biopsy samples,
revealing prevalence rates that ranged from 0 to 15 %
[15, 16] and in healthy adult saliva and oral lavage sam-
ples, revealing prevalence rates between 2.8 and 25 %
[13, 17, 18]. A recent systematic review of the literature
showed oral HPV16 prevalence was 1.3 % among healthy
individuals and appeared to differ by geographic region,
although significant heterogeneity between studies due
to in part to differences in specimen collection, process-
ing and testing limited conclusive interpretation of the
data [19]. There is limited information about the natural
history of oral HPV infection, but since oral HPV16
infection is associated with this cancer, it is important
to estimate the proportion of healthy individuals with
oral HPV infection [19]. The aim of this study was to
estimate the prevalence of HPV-DNA in saliva sam-
ples collected from women in which it has been pre-
viously established the HPV infection of the cervix




This study enrolled 100 women with HPV genital lesions
and 25 healthy women (control group), selected from a
group of 280 women that went to the Gynaecological
Unit of the Riuniti Papardo-Piemonte Hospital, in
Messina, for routine gynaecological screening between
July 2014-October 2015. The control group was selected
on the base of negative Pap-Test from last 3 years.
None of the women enrolled in the study was vacci-
nated for HPV. The gynaecologist, after making sure
of the absence of lesions in the oral cavity, had pro-
vided to us a saliva sample and all the clinical infor-
mation of patients.
After having received their written informed consent,
a detailed anonymous questionnaire was administered in
order to collect information on age, gender, smoking,
drinking and lifetime sexual activity.
Sample collection and DNA isolation
Participants were asked to sit comfortably in an upright
position and tilt their heads down slightly to pool saliva
in the mouth.
The first expectoration was discarded to eliminate
food debris and unwanted substances contaminating the
sample that may cause analytical inaccuracy.
Participants were asked, just after, to briefly (for 30 s)
refrain from swallowing and expectorate however much
saliva was in the mouth from a single expectoration into
a pre-labelled sterile container and ~ 2 mL saliva was
collected. The samples were then immediately refriger-
ated to minimize degradation of salivary proteins until
further processing. To process, the oral rinse was centri-
fuged at 3,000 g for 10 min at 4 °C, the supernatant was
removed and the pellet was resuspended in 10 ml of
sterile normal saline; the centrifugation was repeated
and the salivary pellet was stored at -80 °C until DNA
purification.
DNA extraction
DNA was extracted from saliva cellular pellets using
Puregene DNA purification system (Qiagen, Milan, Italy)
according to manufacturer’s instructions. DNA concen-
tration and quality were estimated by spectrophotometer
measurements of absorbance at 260 and 280 nm and
electrophoresis.
Detection of HPV in the saliva sample
Total saliva DNA was tested for HPV DNA by a PCR
assay using the consensus primers MY09/MY11, which
amplify a fragment of 450 bp within the L1 gene region
of the viral genome (Table 1).
Each PCR run included a negative (sterile water
substituted for DNA) and a positive (DNA sample of an
HPV type 16 carrier) control to monitor contamination
and overall end point sensitivity.
In parallel, each sample was amplified for β-globin to
control for DNA integrity.
PCR reactions were carried out in a total volume of
50 μl containing purified DNA (200 ng), 1x PCR Buffer,
3 mM MgCl2, 1 U of Taq DNA polymerase, 0.2 mM of
dNTP, and 0.3 μM of each primer for HPV genome
(MY09/MY11) or β -globin.
Amplification was performed in a Hybaid PCR
sprint thermocycler with the following profile: an
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initial denaturation step at 94 °C for 10 min,
followed by 40 cycles of denaturation at 94 °C for
1 min, primer annealing at 58 °C for 1 min, and ex-
tension at 72 °C for 1 min; finally, an extension step
of 7 min at 72 °C.
The PCR products were analyzed by 2 % agarose gel
electrophoresis, stained with ethidium bromide and visu-
alized with ultraviolet transilluminator.
Then, HPV-positive samples were amplified with a set
of seven different-HPV-type specific primers. The se-
quences of primers and annealing temperatures used are
given in Table 1.
Statistical analyses
The association between HPV infection and socio-
clinical variables was assessed using chi-square tests,
evaluating the Odds Ratio (OR) and the 95 %
Confidence Interval (CI). Significance was assessed at
the p < 0.05 level. All analyses were performed using
Prism 4.0 software.
Results
Table 2 shows information on age, gender, smoking,
drinking, dietary and sexual habits obtained by anonym-
ous questionnaire.
Saliva samples were collected from 100 women with
HPV cervical lesions, aged between 22 and 52 years old,
and 25 healthy women with normal cytology (control
group), aged between 20 and 49 years old.
In particular, in women with HPV cervical lesions, ac-
cording to the Bethesda System Cytology Classification,
on the basis of lesions, condylomas accounted for 47 %
of the women, low-grade squamous intra-epithelial le-
sions (LSILs) for 28 % and high-grade squamous intra-
epithelial lesions (HSILs) for 25 %.
The information on cervical HPV genotyping supplied
by gynaecologist showed that 42 samples were positive for
low-risk genotypes, and the remaining 58 samples were
positive for high-risk genotypes. Of all HPV cervical sam-
ples, 25 were positive for more than one HPV type.
Considering single and multiple infections, HPV 16
was the most frequent type (19 samples), followed by
types 6 (13 samples), 45 and 11 (8 samples each), 81 (6
samples), 18, 52 and 31 (4 samples each).
The concentration of DNA isolated from all collected
saliva samples was between 100 and 300 ng/μL. Absorb-
ance measurements and A260/A280 ratio analysis
confirmed the purity of the DNA isolates, which aver-
aged between 1.7 and 2.0.
The results of PCR with MY09/MY11 primers showed
that the HPV positive saliva samples were 24 in women
with HPV cervical lesions and 2 in the control group.
Table 1 List of primers and annealing temperatures used in this
study




MY09 CGTCCMARRGGAWACTGATC 58 450
MY11 GCMCAGGGWCATAAYAATGG
HPV6f TAGTGGGCCTATGGCTCGTC 55 280
HPV6r TCCATTAGCCTCCACGGGTG
HPV11f GGAATACATGCGCCATGTGG 58 360
HPV11r CGAGCAGACGTCCGTCCTCG
HPV16f TGCTAGTGCTTATGCAGCAA 55 152
HPV16r ATTTACTGCAACATTGGTAC
HPV18f AAGGATGCTGCACCGGCTGA 58 216
HPV18r CACGCACACGCTTGGCAGGT
HPV31f ATGGTGATGTACACAACACC 55 514
HPV31r GTAGTTGCAGGACAACTGAC
HPV33f ATGATAGATGATGTAACGCC 55 455
HPV33r GCACACTCCATGCGTATCAG
HPV45f ATTTCACAGCATAGCTGGACAGTA 55 100
HPV45r CTATACTTGTGTTTCACTACGTCT
ß-globin f GAAGAGCCAAGGACAGGTAC 57 268
ß-globin r CAACTTCATCCACGTTACC
Table 2 Behavioural factors of studied subjects
Variable HPV negative HPV positive
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Of these positive samples, the characterization of HPV
genotype showed that, in women with HPV cervical le-
sions, 9 woman had a multiple infection (more geno-
types simultaneously), 8 women were infected with one
genotype while 7 women were positive for MY09/MY11
but no specific genotype between those tested was de-
tected. In the control group, 1 woman was infected with
one genotype and 1 woman was positive for MY09/
MY11 but no specific genotype between those tested
was detected (Fig. 1a).
The Fig. 1b shows the genotype characterization, HPV
16 was the most frequent followed by the 18 and then
from 45. The percentage of positivity to low-risk HPV
infection (caused by HPV 6/11) was about 5.26 %.
To investigate in the HPV positive cervical group a
potential risk factor promoting the presence of the virus
in the saliva we correlated this data with the information
collected in the questionnaire.
There was no statistical significance of association be-
tween the HPV positivity and patients’ age, smoking and
drinking alcohol.
Other social and sexual behaviors were not signifi-
cantly associated with the detection of HPV DNA in sal-
iva samples.
Analyzing the data of saliva HPV positivity and
cervical clinical data we revealed a correspondence of
genotypes between saliva and cervix in case of infec-
tions by HPV 16 and 18 supported by a significant
increase of saliva HPV positivity in women with high-
grade cervical lesions (P = 0.0069; OR = 3.747; 95 %
CI: 1.39–10.09) (Fig. 2).
Discussion
The diagnosis of cervical HPV infections generally is not
accompanied by investigations in different sites such as
the oral cavity, except in the presence of visible lesions.
Our results show that patients with genital HPV infection
are at risk for oral infection not always associated with in-
juries. The absence of clinical signs in the oral cavity of
these patients suggests a subclinical infection, and a mo-
lecular assay might thus be necessary to diagnose it.
Highly conserved regions in different parts of the viral
genome have enabled the development of general or
consensus PCR primer sets which allow the detection of
a broad spectrum of different HPV genotypes. However,
differences in malignant potential mean that it is par-
ticularly important to accurately identify infections
with the high-risk HPV genotypes. After amplification
with general or consensus primers, additional tech-
niques are necessary to identify the underlying HPV
genotype [20, 21].
In the present study, we performed a careful oral clin-
ical examination of all patients; no injury was found. We
chose to investigate women with cervical HPV but no
visible lesions in the oral cavity in order to demonstrate
the presence of the virus in saliva even in the absence of
evident clinical signs. This finding indicates that oral
examination alone can not exclude the possibility of oral
HPV infection.
A link between human papillomavirus and oropharyn-
geal cancer was suggested more than 20 years ago [22].
Recent studies of healthy children and adults have found
an oral prevalence of high-risk HPV strains, ranging be-
tween 2.5 and 5 % [17, 19] while previous studies re-
vealed oral-HPV in 20.7 % of women with concomitant
HPV-cervical lesions [13, 23]. Our study highlights that
women with a prior histopathologic diagnosis of cervical
HPV are at high risk for subclinical oral HPV, as indi-
cated by the presence of the virus in the oral cavity of
24 % of the patients. In particular, 70 % were positive to
high-risk (HPV 16-18-31-33-45) and low-risk (6–11)
most frequent HPV genotypes. A significant proportion
(30 %) of subjects has not been characterized; we assume
that the positivity could be due to infection with other
less frequent genotypes. Despite the wide distribution of
HPV in general population, we found a low positivity in
the control used in this study.
Previous studies have shown that current smoking
(and intensity) is associated with oral HPV infection [24,
25]. Actually, even if we did not obtain a significative
statistical correlation between smoking habit and oral
infection, probably because the studied women were
Fig. 1 a Women infected by multiple genotypes simultaneously, one genotype and unknown genotype in saliva samples. b Genotype characterization of
most frequent HPVs in saliva of women with HPV genital lesions and in control group
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occasional smokers, it cannot be excluded a possible
synergy between these two factors. This hypothesis is
suggested by the well known oxidative damage caused
by smoke that is an important risk factor for the HPV
infection as previously shown [26].
Moreover, oral sexual behaviors have been associated
with oral HPV infection and transmission of other viral
infections, such as herpesviruses (HSV) [27]. The major-
ity of the women examinated in our study stated that
don’t have oral sexual habits but we think that this is a
false finding, due to the social conditioning; this is
suggested by the correlation between cervical and oral
genotypes found in our study. A multicenter study re-
vealed a percentage of the HPV detection in oral cancer
specimens higher among subjects who have oral sexual
habits and/or sexual promiscuity [13].
Conclusion
The transmission in the oral cavity of HPV and, conse-
quently, the risk of oral cancer is increased in women
with cervical cancer and in their spouses [13, 28]; this
finding suggests a cross-transmission between the oral
cavity and genitals. Our results, in accordance with the
cited studies, highlight the need to perform an oral
screening test in the women with cervical high risk-HPV
lesions. The correlation between these two anatomic
sites could be consequent to genetic predisposition and/
or conditions of low immune response such as HIV in-
fection [29, 30] that probably favor the colonization and
the persistence of oral HPV [31].
To prevent the cross-transmission, it could be useful
focusing the attention on a correct health education to
reduce the risk of oral and, in general, head and neck
cancer developing. It is important, in our opinion, in-
crease not only correct sexual behaviors but, in general,
healthy lifestyle.
The US Centers for Disease Control and Prevention
(CDC) currently recommends routine HPV vaccination
for females aged 9 to 26 years and males aged 9 to
21 years for the prevention of ano-genital warts and can-
cers based on demonstrated efficacy in randomized clin-
ical trials [32, 33]. Current vaccines approved by the
FDA prevent infections with HPV types 16 and 18, the
two high-risk HPVs that cause about 70% of cervical
cancers and the most part of the other HPV-associated
cancers [10, 34].
Even if the vaccine efficacy against oral HPV infection
is unknown, and therefore the vaccination cannot cur-
rently be recommended for the primary prevention of
oropharyngeal cancer, this practice could be equally use-
ful in the prevention of this kind of cancer considering
that the most detected oral HPV genotypes, in our study,
were HPV-16 and 18 and the strong demonstrated cor-
relation between HSIL and oral HPV positivity.
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